ARNA stock forecast
Our latest prediction for Arena Pharmaceuticals, Inc.'s stock price was made on the Feb. 5, 2020 when the stock price was at 49.62$.
In the short term (2weeks), ARNA's stock price should underperform the market by -2.57%. During that period the price should oscillate between -7.84% and +7.13%.
In the medium term (3months), ARNA's stock price should underperform the market by -6.69%. During that period the price should oscillate between -30.93% and +18.98%.Get email alerts
Create a solid portfolio with ARNA
About Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.
At the moment the company generates 812M USD in revenues.
On its last earning announcement, the company reported a profit of 10.88$ per share.
The book value per share is 11.32$
Three months stock forecastFeb. 5, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|